Retatrutide
LY3437943, LY-3437943
Investigational triple receptor agonist with published phase 3 trials. Not approved by FDA, EMA, the MHRA or the TGA, the four regulators checked.
The one area of peptide research with large randomised human trials and approved medicines, alongside compounds that have neither.
This is the exception in peptide research. GLP-1 receptor agonists have been through large randomised trials with hard endpoints, and several are approved medicines with published regulatory assessments.
That makes the contrast within this hub stark. Some entries here rest on thousands of trial participants. Others rest on rodent studies. The evidence labels are doing real work.
LY3437943, LY-3437943
Investigational triple receptor agonist with published phase 3 trials. Not approved by FDA, EMA, the MHRA or the TGA, the four regulators checked.
Ozempic, Wegovy, Rybelsus
A GLP-1 receptor agonist approved in the US and EU for type 2 diabetes and weight management, with cardiovascular and kidney outcome trials.
Egrifta, Egrifta SV, Egrifta WR, TH9507
A growth hormone-releasing hormone analogue approved in the US for one use: excess abdominal fat in adults with HIV and lipodystrophy.
LY3298176, Mounjaro, Zepbound
Tirzepatide is a dual GIP and GLP-1 receptor agonist, approved in the US and the EU for type 2 diabetes and for weight management.
Safety
No. FDA has not approved retatrutide and says it cannot be compounded. What regulators found in products sold under its name, and what is unknown.
Comparison
No trial has yet compared retatrutide with tirzepatide directly. What each drug's own trials show, and what the published ranking rests on.
Evidence review
Seven retatrutide trials have published results, three in phase 3, all run by Eli Lilly: what each found, and what has not yet reported.